Lytix Biopharma

Lytix Biopharma is a private clinical-stage biotechnology company, a pharmaceutical company engaged in antimicrobial and cancer therapies, committed to developing proprietary oncolytic peptides as a novel immunotherapy for cancer. The lead compound LTX-315 generates antigens by using the patient's own tumor as an antigen source and turns cold tumors hot. Local treatment with LTX-315 targets the first step of the cancer-immunity cycle and has potential as a cornerstone in immunotherapy.